These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 646850)

  • 21. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
    Heinrich J; Schulte H; Schönfeld R; Köhler E; Assmann G
    Thromb Haemost; 1995 Mar; 73(3):374-9. PubMed ID: 7667818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood rheology changes during bezafibrate treatment.
    Caimi G; Francavilla G; Romano A; Catania A; Santonocito G; Sarno A
    Br J Clin Pract; 1988 Nov; 42(11):456-8. PubMed ID: 3076782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [On fibrinogen in atherosclerosis and hypertension].
    Atanasov K
    Folia Med (Plovdiv); 1967; 9(5):270-4. PubMed ID: 4972391
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prothrombin time, activated partial thromboplastin time, plasma fibrinogen determination. Comparison of two automated coagulation systems: Koagulab 40-A and ACL-100].
    Barbe D; Bauduer F; Tanguy A
    Ann Biol Clin (Paris); 1991; 49(10):507-13. PubMed ID: 1807170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrin formation and degradation in patients with arteriosclerotic disease.
    Herren T; Stricker H; Haeberli A; Do DD; Straub PW
    Circulation; 1994 Dec; 90(6):2679-86. PubMed ID: 7994808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [On the problem of atherosclerosis in liver cirrhosis].
    Loginov AS; Iutanova II
    Kardiologiia; 1967 Apr; 7(4):29-33. PubMed ID: 5598470
    [No Abstract]   [Full Text] [Related]  

  • 27. [Behavior of parameters of the blood coagulation and fibrinolytic system in patients with peripheral arteriosclerotic angio-organopathy and in patients after acute phlebothrombosis].
    Siegert G; Runge E
    Vasa Suppl; 1992; 35():89-91. PubMed ID: 1481076
    [No Abstract]   [Full Text] [Related]  

  • 28. D-dimers in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction.
    Tataru MC; Heinrich J; Junker R; Schulte H; von Eckardstein A; Assmann G; Koehler E
    Eur Heart J; 1999 Oct; 20(20):1493-502. PubMed ID: 10493848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen is an independent marker for thoracic aortic atherosclerosis.
    Tribouilloy C; Peltier M; Colas L; Senni M; Ganry O; Rey JL; Lesbre JP
    Am J Cardiol; 1998 Feb; 81(3):321-6. PubMed ID: 9468075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of fibrinogen in arterial vascular pathology].
    Colorio CC; Falcón CR; Carreras LO
    Sangre (Barc); 1997 Feb; 42(1):47-52. PubMed ID: 9097719
    [No Abstract]   [Full Text] [Related]  

  • 31. [Chronic peripheral arterial occlusive disease, platelet glycoproteins GPIIb-IIIa and GP Ib-IX, plasma von Willebrand factor and plasma fibrinogen concentrations in patients with type 2 diabetes mellitus].
    Gosk-Bierska I; Adamiec R; Doskocz W; Ciosek W
    Pol Arch Med Wewn; 2000; 103(3-4):139-45. PubMed ID: 11236240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selected biochemical components of plasma and blood viscosity in patients with arteriosclerosis].
    Turczyński B; Znamirowska D; Szczesny S; Grzegorczyn S
    Pol Arch Med Wewn; 1987 Jun; 77(6):300-5. PubMed ID: 3271281
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis.
    Jaeger BR
    Ther Apher; 2001 Jun; 5(3):207-11. PubMed ID: 11467757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fibrinogen as a cardiovascular risk factor--marker or causal factor?].
    Halvorsen S
    Tidsskr Nor Laegeforen; 1999 Aug; 119(19):2829-32. PubMed ID: 10494205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Fibrinogen as an independent cardiovascular risk factor and the question of treatment with fibrinogen-lowering drugs].
    Boda Z
    Orv Hetil; 1997 Sep; 138(39):2455-60. PubMed ID: 9380384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fibrinogen and atherothrombosis: vulnerable plaque or vulnerable patient?].
    Jaeger BR; Labarrere CA
    Herz; 2003 Sep; 28(6):530-8. PubMed ID: 14569394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasma viscosity in atherosclerotic patients].
    Turczyński B; Sroczyński J; Kossmann S
    Pol Tyg Lek; 1976 Aug; 31(33):1423-5. PubMed ID: 62351
    [No Abstract]   [Full Text] [Related]  

  • 39. Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.
    Temelkova-Kurktschiev T; Koehler C; Henkel E; Hanefeld M
    Cardiovasc Res; 2002 Nov; 56(2):277-83. PubMed ID: 12393098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered endogenous fibrinolysis and biochemical factors in atherosclerosis.
    Peabody RA; Tsapogas MJ; Wu KT; Deveraj KT; Karmody AM; Eckert C
    Arch Surg; 1974 Aug; 109(2):309-13. PubMed ID: 4276947
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.